Comparative Pharmacology
Head-to-head clinical analysis: ATROMID S versus BEKYREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATROMID S versus BEKYREE.
ATROMID-S vs BEKYREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits hepatic triglyceride synthesis and increases lipoprotein lipase activity, leading to reduced VLDL and triglycerides.
BEKYREE (balcinrenone) is a selective mineralocorticoid receptor antagonist that binds to the mineralocorticoid receptor, inhibiting aldosterone-mediated sodium reabsorption and reducing inflammation and fibrosis in the kidney and heart.
500 mg to 1 g orally twice daily. Maximum dose 2 g/day.
1 mg/kg intravenously every 4 weeks; maximum dose 100 mg.
None Documented
None Documented
Terminal elimination half-life is 6-8 hours in patients with normal renal function; may be prolonged to 12-24 hours in renal impairment.
Terminal elimination half-life: 12 hours (range 10-14 h); prolonged in renal impairment (up to 30 h in CrCl <30 mL/min)
Primarily renal excretion as glucuronide conjugates; approximately 60-70% of the dose is excreted in urine, 20-30% in feces via biliary elimination.
Renal: 70% (unchanged drug), Biliary/fecal: 30% (metabolites and unchanged drug)
Category C
Category C
Antilipemic Agent
Antilipemic Agent